NO890587L - Nye proteiner med faktor viii aktivitet: fremgangsmaate for fremstilling derav ved anvendelse av genetisk omkonstruerte celler og farmasoeytiske sammensetninger som inneholderdisse. - Google Patents

Nye proteiner med faktor viii aktivitet: fremgangsmaate for fremstilling derav ved anvendelse av genetisk omkonstruerte celler og farmasoeytiske sammensetninger som inneholderdisse.

Info

Publication number
NO890587L
NO890587L NO89890587A NO890587A NO890587L NO 890587 L NO890587 L NO 890587L NO 89890587 A NO89890587 A NO 89890587A NO 890587 A NO890587 A NO 890587A NO 890587 L NO890587 L NO 890587L
Authority
NO
Norway
Prior art keywords
factor viii
preparation
genetic
procedure
content
Prior art date
Application number
NO89890587A
Other languages
English (en)
Other versions
NO890587D0 (no
NO301121B1 (no
Inventor
Albert Johannes Joseph V Ooyen
Hans Pannekoek
Martinus Philippus Verbeet
Robert Willem Van Leen
Original Assignee
Stichting Centr Lab V Bloedtra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Centr Lab V Bloedtra filed Critical Stichting Centr Lab V Bloedtra
Publication of NO890587L publication Critical patent/NO890587L/no
Publication of NO890587D0 publication Critical patent/NO890587D0/no
Publication of NO301121B1 publication Critical patent/NO301121B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO890587A 1987-06-12 1989-02-10 Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav NO301121B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87201121 1987-06-12
PCT/NL1988/000028 WO1988009813A1 (en) 1987-06-12 1988-06-13 Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
NO890587L true NO890587L (no) 1989-02-10
NO890587D0 NO890587D0 (no) 1989-02-10
NO301121B1 NO301121B1 (no) 1997-09-15

Family

ID=8197627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO890587A NO301121B1 (no) 1987-06-12 1989-02-10 Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav

Country Status (19)

Country Link
US (2) US5171844A (no)
JP (1) JP2771827B2 (no)
KR (1) KR970002915B1 (no)
CN (1) CN1033760C (no)
AT (2) ATE142691T1 (no)
CA (1) CA1341208C (no)
DE (2) DE3855523T2 (no)
DK (1) DK172631B1 (no)
ES (2) ES2169095T3 (no)
FI (1) FI103731B (no)
GR (1) GR3021545T3 (no)
HU (2) HU213300B (no)
IE (1) IE69026B1 (no)
IL (1) IL86693A (no)
NO (1) NO301121B1 (no)
NZ (1) NZ224992A (no)
PT (1) PT87721B (no)
WO (1) WO1988009813A1 (no)
ZA (1) ZA884216B (no)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
FR2657884B1 (fr) * 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
CA2091266A1 (en) * 1990-09-14 1992-03-15 Patricia Tekamp-Olson Expression of macrophage inducible proteins (mips) in yeast cells
US20060122376A1 (en) * 1991-02-07 2006-06-08 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU5989796A (en) * 1995-06-06 1996-12-24 Board Of Regents Of The University Of Nebraska, by and on behalf of The University Of Nebraska Medical Center, The Organ function replacement compositions and methods of makin g and using the same
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
WO1999029848A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1325681A1 (en) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
AU2003241599A1 (en) * 2002-05-22 2003-12-12 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
TWI492951B (zh) * 2007-12-31 2015-07-21 Baxter Int 表現人類凝血因子的基因轉殖非人類動物及其用途
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
CN103796670A (zh) 2011-07-08 2014-05-14 比奥根艾迪克依蒙菲利亚公司 因子viii嵌合和杂合多肽及其使用方法
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
EP3970737A1 (en) 2012-01-12 2022-03-23 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
DK2968477T3 (da) 2013-03-15 2020-03-09 Bioverativ Therapeutics Inc Faktor viii-polypeptidformuleringer
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
SG10201710616XA (en) 2013-06-28 2018-02-27 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
CN105017410B (zh) * 2014-04-18 2018-06-08 北京诺思兰德生物技术股份有限公司 一种b区部分缺失型重组人凝血因子ⅷ
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN115074366A (zh) 2015-04-16 2022-09-20 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
EP3374387A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EA202092049A1 (ru) 2015-11-13 2020-11-10 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
WO2017136358A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
CN109790529A (zh) 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
TW202545984A (zh) 2017-08-09 2025-12-01 美商生物化學醫療公司 核酸分子及其用途
KR101952102B1 (ko) * 2017-12-07 2019-02-26 주식회사 지앤피바이오사이언스 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
IL312315A (en) 2018-04-04 2024-06-01 Sigilon Therapeutics Inc Implantable particles and related methods
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
EP3823985A1 (en) 2018-07-16 2021-05-26 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
US20220233650A1 (en) 2019-06-19 2022-07-28 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
JP2023537070A (ja) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用
EP4355768A1 (en) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
CA3229323A1 (en) 2021-08-23 2023-03-02 Ajay MAGHODIA Optimized factor viii genes
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857635A (en) 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
US4657894A (en) 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US4886876A (en) 1983-03-31 1989-12-12 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE72838T1 (de) * 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US4769336A (en) 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (fr) 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH025890A (ja) 1988-06-24 1990-01-10 Chemo Sero Therapeut Res Inst ニワトリのβ−アクチンプロモーターを用いたヒトファクター８Ｃの製造方法
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Also Published As

Publication number Publication date
FI103731B1 (fi) 1999-08-31
IL86693A0 (en) 1988-11-30
FI890643L (fi) 1989-02-10
DE3856505T2 (de) 2002-08-08
DK172631B1 (da) 1999-03-22
NZ224992A (en) 1991-07-26
IE881755L (en) 1988-12-12
HU213300B (en) 1997-05-28
PT87721A (pt) 1988-07-01
DE3855523T2 (de) 1997-02-06
WO1988009813A1 (en) 1988-12-15
FI890643A0 (fi) 1989-02-10
ZA884216B (en) 1989-02-22
IE69026B1 (en) 1996-08-07
DE3856505D1 (de) 2002-01-10
GR3021545T3 (en) 1997-02-28
US5171844A (en) 1992-12-15
KR970002915B1 (ko) 1997-03-12
JP2771827B2 (ja) 1998-07-02
US6316226B1 (en) 2001-11-13
CN1033760C (zh) 1997-01-08
ATE209679T1 (de) 2001-12-15
NO890587D0 (no) 1989-02-10
PT87721B (pt) 1992-10-30
NO301121B1 (no) 1997-09-15
HU211503A9 (en) 1995-11-28
DK58789D0 (da) 1989-02-09
CA1341208C (en) 2001-03-27
ATE142691T1 (de) 1996-09-15
ES2169095T3 (es) 2002-07-01
KR890701739A (ko) 1989-12-21
CN1030609A (zh) 1989-01-25
FI103731B (fi) 1999-08-31
DK58789A (da) 1989-02-09
IL86693A (en) 1994-06-24
JPH02500484A (ja) 1990-02-22
ES2094111T3 (es) 1997-01-16
DE3855523D1 (de) 1996-10-17

Similar Documents

Publication Publication Date Title
NO890587L (no) Nye proteiner med faktor viii aktivitet: fremgangsmaate for fremstilling derav ved anvendelse av genetisk omkonstruerte celler og farmasoeytiske sammensetninger som inneholderdisse.
ES2147720T3 (es) Factor de celulas madre.
DK2285D0 (da) Osteogen faktor og middel indeholdende denne faktor
ATE188383T1 (de) Mischungen zum schutz und regenierung von geweben
IL93508A0 (en) Novel benzimidazole and azabenimidazole derivatives,their methods of preparation,synthesis intermediates and pharmaceutical compositions in which they are present and which are useful especially for the treatment of cardiovascular diseases and duodenal ulcers
NO165625C (no) Middel for kosmetisk hudpleie og fremgangsmaate ved fremstilling derav.
NZ223551A (en) Human interleukin-3 and related proteins, production of these using genetic engineering methods and pharmaceutical compositions
NO883229L (no) Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater.
PT80300A (de) Herstellung von polypeptiden mit human-gammainterferonaktivitat
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DK124787D0 (da) Peptider indeholdende op til 8-aminosyregrupperinger og fysiologisk uskadelige salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter ved fremstillingen
ATE46146T1 (de) Phenylpiperidinderivat und seine salze, ihre herstellung, sie enthaltende zusammensetzungen und ihre therapeutische verwendung.
EP0286441A3 (en) Novel cytotoxic protein
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
SE8701934L (sv) Okad expression av humant interleukin-2 i deggdjursceller
BG50159A3 (bg) Метод за получаване на производни на пиранобензоксадиазол
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
DK0505400T3 (da) N-substituerede naphthalimider, deres fremstilling og anvendelse
MY105110A (en) Low molecular weight derivatives of prourokinase and pharmaceutical compositions containing the same
RU95101019A (ru) Способ получения фактора некроза опухоли, фактор некроза опухоли, днк, клетка, композиция
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
ATE98679T1 (de) Herstellung des hblv-virus in der hsb-2 zelllinie.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees